Optimal Cost-Effective Designs of Phase II Proof of Concept Trials and Associated Go–No Go Decisions-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal Cost-Effective Designs of Phase II Proof of Concept Trials and Associated Go–No Go Decisions

Published:2009-04-21 Issue:3 Volume:19 Page:424-436
ISSN:1054-3406
Container-title:Journal of Biopharmaceutical Statistics
language:en
Short-container-title:Journal of Biopharmaceutical Statistics

Author:

Chen Cong¹,Beckman∗ Robert A.²³

Affiliation:

1. a Biostatistics and Research Decision Sciences , Merck Research Laboratories (MRL) , Upper Gwynedd, Pennsylvania, USA

2. b Oncology/Clinical Research , Merck Research Laboratories , Upper Gwynedd, Pennsylvania, USA

3. c Simons Center for Systems Biology , Institute for Advanced Study , Princeton, New Jersey, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Link

https://www.tandfonline.com/doi/pdf/10.1080/10543400902800478

Reference10 articles.

1. New designs for phase 2 clinical trials

2. The sample size for a clinical trial: A Bayesian-decision theoretic approach

3. Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

4. Bayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness

5. Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Two-Stage Covariate-Adjusted Response-Adaptive Enrichment Design;Statistics in Biopharmaceutical Research;2024-02-26

2. Aiding the Adoption of Master Protocols by Optimizing Patient Engagement;Therapeutic Innovation & Regulatory Science;2023-08-24

3. Bayesian Complex Innovative Trial Designs (CIDs) and Their Use in Drug Development for Rare Disease;The Journal of Clinical Pharmacology;2022-12

4. Innovations in Clinical Development in Rare Diseases of Children and Adults: Small Populations and/or Small Patients;Pediatric Drugs;2022-10-15

5. What is the expected benefit of patient-centric clinical development in oncology?;Journal of Biopharmaceutical Statistics;2022-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3